Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $9.31 Consensus PT from Brokerages

Trevi Therapeutics, Inc. (NASDAQ:TRVI) has been given an average recommendation of “Buy” by the ten analysts that are currently covering the company, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $9.31.

A number of equities research analysts have recently commented on the stock. D. Boral Capital reiterated a “buy” rating and set a $21.00 price target on shares of Trevi Therapeutics in a report on Wednesday, January 8th. Needham & Company LLC reissued a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a report on Thursday, December 12th. Finally, HC Wainwright boosted their price objective on Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a research note on Thursday, December 12th.

Institutional Investors Weigh In On Trevi Therapeutics

A number of institutional investors have recently added to or reduced their stakes in TRVI. Frazier Life Sciences Management L.P. raised its holdings in Trevi Therapeutics by 44.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company’s stock worth $43,939,000 after purchasing an additional 3,283,684 shares in the last quarter. Woodline Partners LP lifted its position in Trevi Therapeutics by 429.9% during the fourth quarter. Woodline Partners LP now owns 3,212,597 shares of the company’s stock valued at $13,236,000 after acquiring an additional 2,606,370 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in Trevi Therapeutics in the fourth quarter valued at approximately $58,000. Two Sigma Advisers LP purchased a new position in Trevi Therapeutics in the fourth quarter worth $66,000. Finally, Two Sigma Investments LP acquired a new position in shares of Trevi Therapeutics during the fourth quarter worth $560,000. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Stock Performance

TRVI stock opened at $4.60 on Friday. The firm has a market capitalization of $353.60 million, a price-to-earnings ratio of -10.45 and a beta of 0.88. The firm has a 50 day moving average price of $4.09 and a 200-day moving average price of $3.39. Trevi Therapeutics has a 52-week low of $2.30 and a 52-week high of $5.05.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.